Assessment of patients post reversal with idarucizumab
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-018-1723-1
Abstract: Idarucizumab, a fully humanized Fab antibody fragment, is indicated for reversal of dabigatran’s anticoagulant activity. Idarucizumab neutralizes the anticoagulant effects of dabigatran by binding to dabigatran and its metabolite. In the full analysis of 503… read more here.
Keywords: reversal; emergent procedure; cohort; dabigatran ... See more keywords